Skip to main content
    C

    CG Oncology, Inc. Common stock (CGON)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $75.99
    +11.19 (+17.27%)

    Market Cap: $5.74B

    Last updated: Nov 06, 2026 at 4:34 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    27%(3/11)
    Avg Surprise
    -15.70%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.81
    Range$-0.96 - $-0.66
    12 analysts
    EPS RevisionsNo revisions (7d)
    0
    10
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.68-19.1%
    60d ago$-0.810.0%
    30d ago$-0.810.0%
    7d ago$-0.810.0%
    Current$-0.81
    Revenue Consensus
    $534480
    Range$0 - $1M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.24
    Range$-1.61 - $-0.80
    12 analysts
    Revenue Consensus
    $3M
    Range$649850 - $17M
    13 analysts
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-1.24$-1.61 - $-0.80--12--
    Sep 26EST
    		-$-0.81$-0.96 - $-0.66--12
    0
    10
    30d
    		-
    Jun 26
    Reported Aug 6
    		$-0.90$-0.70$-0.73 - $-0.52-28.57%Miss11
    3
    6
    30d
    		-66.7%
    Mar 26
    Reported May 8
    		$-0.71$-0.58$-0.66 - $-0.43-22.41%Miss10
    5
    0
    30d
    		-57.8%
    Dec 25
    Reported Feb 27
    		$-0.51$-0.48$-0.57 - $-0.40-6.25%Miss12
    2
    5
    30d
    		-10.9%
    Sep 25
    Reported Nov 14
    		$-0.57$-0.55$-0.63 - $-0.48-3.64%Miss10
    0
    1
    30d
    		-90.0%
    Jun 25
    Reported Aug 8
    		$-0.54$-0.45$-0.50 - $-0.37-20.00%Miss8
    2
    1
    30d
    		-92.9%
    Mar 25
    Reported May 13
    		$-0.45$-0.37$-0.51 - $-0.13-21.62%Miss5
    0
    1
    30d
    		-25.0%
    Dec 24
    Reported Mar 28
    		$-0.46$-0.45$-0.45 - $-0.45-2.22%Miss1
    1
    1
    30d
    		-39.0%
    Sep 24
    Reported Nov 14
    		$-0.30$-0.34$-0.57 - $-0.28+11.76%Beat5
    1
    0
    30d
    		-
    Jun 24
    Reported Aug 8
    		$-0.28$-0.31$-0.53 - $-0.23+9.68%Beat5
    1
    0
    30d
    		-
    Mar 24
    Reported May 9
    		$-0.36$-0.15--140.00%Miss---
    Dec 23
    Reported Mar 26
    		$-0.33N/A-+50.61%Beat---

    Key Metrics

    Valuation
    P/E Ratio-28.25EV/EBITDAN/A
    Price/FCF-35.70xFCF Yield-2.80%
    Profitability
    Profit Margin0.00%Operating Margin-7468.00%
    ROE-26.40%ROIC-21.06%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio21.70xQuick Ratio21.68x
    Trading Statistics
    Beta0.35Avg Volume1.04M
    52-Week High$80.9752-Week Low$35.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$65.11
    SMA 20$63.43
    SMA 50$68.24
    SMA 200$66.20
    EMA 10$66.27
    EMA 20$65.37
    EMA 50$67.12
    EMA 200$63.42

    MACD

    Line: 0.23Signal: -1.22Hist: 1.46

    ADX

    ADX: 20.4+DI: 35.8-DI: 11.6

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down44.0
    PSAR$62.54

    Bollinger Bands

    Upper Band$70.30
    Lower Band$56.55
    %B Position2168%(Upper)
    Band Width1.41

    RSI (14-Day)

    Neutral
    67.7

    Momentum Oscillators

    Stoch %K80.8
    Stoch %D76.9
    Williams %R-20.0
    ROC (10d)23.1%
    Momentum14.28
    CCI (20d)402.8
    MFI (14d)73.8

    Volatility Measures

    ATR (14d)$4.01(5.3%)
    StdDev (20d)3.44
    Hist Vol72.7%(High)

    Volume Flow

    VWAP$74.16
    OBV26.7M
    AD Line18.9M
    CMF (20d)0.041

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio3.4x(High)
    VWMA (20d)$65.02

    Pivot Points

    R3$69.89
    R2$68.61
    R1$66.71
    Pivot Point$65.43
    S1$63.53
    S2$62.25
    S3$60.35

    Advanced Oscillators

    TSI1.58
    Ultimate Osc60.6
    KST-44.50

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$1.60M$1.16M$1.08M$2.32M$1.67M$0$52,000$567,000$43,000$0$529,000$1,000
    Cost of Revenue$2.67M$3.92M$2.96M$3.07M$1.58M$0$0N/A$0$0$0$4,000
    Gross Profit$-1,065,000$-2,768,000$-1,879,000$-748,000$89,000$0$52,000$567,000$43,000$0$529,000$1,000
    Operating Expenses$62.18M$83.63M$64.51M$47.95M$51.22M$48.74M$42.26M$38.51M$28.34M$25.96M$23.00M$19.36M
    R&D$39.22M$54.66M$43.73M$29.96M$27.88M$31.33M$27.47M$26.80M$19.62M$18.47M$17.21M$16.34M
    SG&A$22.96M$28.98M$20.78M$17.99M$23.33M$17.41M$14.79M$11.71M$8.72M$7.49M$5.79M$3.02M
    Operating Income$-63,249,000$-86,401,000$-66,389,000$-48,700,000$-51,129,000$-48,741,000$-42,204,000$-38,049,000$-28,295,000$-25,853,000$-22,469,000$-19,359,000
    Interest Income$6.42M$7.33M$6.29M$7.44M$7.42M$7.32M$7.75M$6.25M$7.89M$6.94M$5.54M$2.80M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-56,891,000$-79,056,000$-60,202,000$-41,309,000$-43,808,000$-41,426,000$-34,452,000$-31,798,000$-20,405,000$-18,902,000$-16,934,000$-16,559,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-56,891,000$-79,056,000$-60,202,000$-41,309,000$-43,808,000$-41,426,000$-34,452,000$-31,798,000$-20,405,000$-18,902,000$-16,934,000$-16,559,000
    EBITDA$-62,159,000$-85,535,000$-65,649,000$-46,953,000$-50,813,000$-48,589,000$-42,175,000$-36,788,000$-29,858,000$-28,304,000$-24,673,000$-20,814,000
    EBIT$-63,314,000$-86,385,000$-66,490,000$-48,753,000$-51,229,000$-48,745,000$-42,199,000$-38,043,000$-28,297,000$-25,845,000$-22,478,000$-19,363,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CGON

    News

    CG Oncology, Inc. (CGON) Misses Q3 EPS by 4c

    CG Oncology, Inc. (NASDAQ: CGON) reported a Q3 EPS of ($0.64), missing analyst estimates by $0.04. The company also announced revenue for the quarter came in at $1.6 million. The stock price was up 17.27% today...

    StreetInsider•11/6/26•Bearish

    CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue Estimates

    CG Oncology, Inc. (CGON) reported a Q3 loss of $0.64 per share, surpassing the Zacks Consensus Estimate of a $0.86 loss and an earnings surprise of +25.58%. The company also exceeded revenue estimates...

    Yahoo Finance•11/6/26•Somewhat-Bullish

    With $984.5M in cash and securities, CG Oncology (CGON) posts a wider Q3 loss.

    CG Oncology (CGON) reported a wider net loss of $56.9 million in Q3 2026, compared to $43.8 million in Q3 2025, and a nine-month net loss of $196.1 million. Despite the losses...

    Stock Titan•11/6/26•Neutral

    CG Oncology, Inc. (CGON) Stock Price, News, Quote & History

    CG Oncology, Inc. (CGON) closed at $67.71, up 5.70%, on November 4th, with significant year-to-date and one-year returns of 63.08% and 73.30% respectively. The biopharmaceutical company is actively developing...

    Yahoo! Finance Canada•11/4/26•Somewhat-Bullish

    Genmab Share Price Surge Puts These Oncology Stocks In Focus

    Following Genmab's significant share price surge and three Phase 3 wins, attention is turning to other oncology biotech companies. This article examines three specific oncology stocks—CG Oncology, BeOne Medicines...

    Simply Wall St•11/3/26•Bullish

    CGON Valuation and Fair Value

    P/E
    -28.2x
    P/FCF
    -35.7x
    P/B
    6.8x
    See GNG's fair value

    CGON Profitability: Margins, ROIC and FCF

    Gross margin
    -104.8%
    Operating margin
    -7468.0%
    Net margin
    0.0%
    ROIC
    -21.1%
    ROE
    -26.4%
    FCF margin
    -3068.0%
    FCF yield
    -2.8%

    CGON Competitors

    CompanyTicker
    Grifols SA ADRGRFS
    Kodiak Sciences IncKOD
    Immunovant IncIMVT
    Haemonetics CorporationHAE
    Ligand Pharmaceuticals IncorporatedLGND
    Waystar Holding Corp. Common StockWAY
    Mirum Pharmaceuticals IncMIRM
    Scholar Rock Holding CorpSRRK

    Sector: Healthcare

    CGON Analyst Ratings

    Consensus
    Buy
    Analysts
    15
    Strong Buy
    4
    Buy
    10
    Hold
    1
    Sell
    0
    Strong Sell
    0

    CGON Bull Case vs Bear Case

    Bull case

    • CGON grew quarterly revenue 1983.0% year over year.
    • 93.3% of CGON's analyst ratings are Buy or Strong Buy.

    Bear case

    • CGON beat EPS estimates in 12.5% of its last 8 reported quarters.

    CGON Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -11.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.81
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 10 down

    CGON Earnings Date

    CGON reports Nov 12, 2026. The date is estimated.

    CGON ETF Holders

    GNG tracks 14 ETFs that hold CGON. The largest weights:

    1. State Street SPDR S&P Biotech ETF (XBI), 0.96% of the fund
    2. iShares Biotechnology ETF (IBB), 0.26% of the fund
    3. Fidelity Enhanced Small Cap Core ETF (FESM), 0.19% of the fund
    4. Vanguard Morningstar Small-Cap Growth ETF (VBK), 0.16% of the fund
    5. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.08% of the fund
    Open the ETF Stock Exposure tool for CGON

    Frequently Asked Questions About CGON

    When does CGON report earnings?

    CG Oncology, Inc. Common stock (CGON) is expected to report earnings on Nov 12, 2026.

    Does CGON pay dividends?

    CG Oncology, Inc. Common stock (CGON) does not currently pay a regular dividend.

    What is CGON's market cap?

    CG Oncology, Inc. Common stock (CGON) has a market capitalization of $5.74B with a current stock price of $75.99.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In